Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Enzolytics Inc
(OP:
ENZC
)
0.0004
UNCHANGED
Streaming Delayed Price
Updated: 3:07 PM EST, Jan 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Enzolytics Inc
< Previous
1
2
3
Next >
Enzolytics Inc. Files Supplemental Information Report on the Sale of Biogenysis, Inc. and Virogentics, Inc to Sagaliam Acquisition Corp.
July 11, 2023
Via
ACCESSWIRE
Virogentics, Inc to Introduce a Dietary Supplement Offers Additional Information on ITV-1 And Diabetic Clinical Trials
July 06, 2023
Via
ACCESSWIRE
Enzolytics, Inc. Reports Amendment to Non-Binding Term Sheet with the Special Purpose Acquisition Company Sagaliam Acquisition Corp.
June 29, 2023
Via
ACCESSWIRE
Enzolytics Offers Update on Virogentics, Inc ITV-1 African Project
June 26, 2023
Via
ACCESSWIRE
Stock Market Surges “Milestones Reached”: SWISF / SKUR.C, NWBO, ENZC, ABML
June 12, 2023
Via
AB Newswire
Enzolytics Offers Update on Virogentics and Sale Transaction, Clinical Trials Progress on European Medicine Agency (EMA) Permitting and Arican ITV-1 Project
June 05, 2023
Via
ACCESSWIRE
Virogentics and Enzolytics Refute Misleading Information Being Circulated on Social Media and Other Internet Outlets Biogenesis to be Featured in June Issue of Life Science Review
May 19, 2023
Via
ACCESSWIRE
Enzolytics Announces Progress in the Development and Patenting of Feline Leukemia Monoclonal Antibodies
April 04, 2023
Via
ACCESSWIRE
Enzolytics, Inc. Highlights Plans for Promotion of IPF Immune(TM), Its Patented Nutraceutical Supplement
February 28, 2023
Via
ACCESSWIRE
Virogentics Inc. Receives Report from Bulgarian Academy of Sciences Administration of ITV-1 to Begin First Week in June 2023
May 16, 2023
Via
ACCESSWIRE
Undervalued Biotech Stocks to Watch After Enzolytics’ (OTC:ENZC) 300% Run: RMED, SPPI, HALB, VXRT
May 12, 2023
Via
AB Newswire
Virogentics Inc. Announces Pilot Clinical Trial of ITV-1 at National Center for Endocrinology in Bulgaria and Expansion of Nutraceutical Line
May 08, 2023
Via
ACCESSWIRE
Enzolytics Inc. Continues Progress with Business Combination; Biogenysis Announces Team and Plans for Success
April 27, 2023
Via
ACCESSWIRE
Enzolytics, Inc. Finalizing Regulatory Labeling Requirements for Delivery of ITV-1 Treatments for Use in Hospitals in Central and Eastern Africa - Company also Provides Additional Details on the Sale of Biogenysis and Virogentics
April 21, 2023
Via
ACCESSWIRE
Enzolytics to Develop Feline Monoclonal Antibodies
January 03, 2023
Via
ACCESSWIRE
Enzolytics, Inc. Announces the Completion of the 2020 and 2021 Audited Financials
December 19, 2022
Via
ACCESSWIRE
Enzolytics, Inc. Announces U.S. Distribution of IPF Immune(TM) and Progress in each of its Therapeutic Platforms
December 13, 2022
Via
ACCESSWIRE
Enzolytics, Inc. Announces Execution of Non-Binding Term Sheet with the Special Purpose Acquisition Company Sagaliam Acquisition Corp. and Updates the Progress on the African Project
April 17, 2023
Via
ACCESSWIRE
Enzolytics Announces Preliminary Results of GLP Toxicology Study for its anti-HIV Therapeutic ITV-1 and Production of ITV-1 for Initiation of Registration in Africa
February 08, 2023
Via
ACCESSWIRE
Enzolytics Recognizes World AIDS Day and Highlights the Company's Focus on Producing Effective Therapies for Treating HIV
December 01, 2022
Via
ACCESSWIRE
Enzolytics, Inc. Announces Expansion of Production of Its Monoclonal Antibody Therapeutics and Marketing of IPF Immune(TM)
November 16, 2022
Via
ACCESSWIRE
Enzolytics, Inc. Announces New Advisory Board Member
October 24, 2022
Via
ACCESSWIRE
Enzolytics Reports Successful Completion of an MTD Tolerability Study of Its ITV-1 anti-HIV Therapeutic Leading to the Start of a 28-day GLP Toxicology Study
October 05, 2022
Via
ACCESSWIRE
Enzolytics Inc. Announces Collaboration with Abveris to Discover Monoclonal Antibodies
September 16, 2022
Via
ACCESSWIRE
Enzolytics Inc. Announces Litigation Success, Accounting Progress and Removal of "Yield" Sign on OTC Markets Stock Quotes
September 14, 2022
Via
ACCESSWIRE
Enzolytics Announces the International Patent Office Search Report finding Novelty and Inventiveness in the Company's Pending International Patent Application Covering its anti-HIV Monoclonal Antibodies.
July 28, 2022
COLLEGE STATION, TX / ACCESSWIRE / July 28, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) ("ENZC" or the "Company"). In the first Official Action on the Company's International Patent Application covering...
From
Enzolytics, Inc.
Via
AccessWire
Topics
Intellectual Property
Enzolytics Announces the International Patent Office Search Report finding Novelty and Inventiveness in the Company's Pending International Patent Application Covering its anti-HIV Monoclonal Antibodies.
July 28, 2022
Via
ACCESSWIRE
Enzolytics Announces the Discovery of Conserved Target Sites on the Monkeypox Virus
June 21, 2022
COLLEGE STATION, TX / ACCESSWIRE / June 21, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (ENZC" or the "Company") today announced it has identified conserved, immutable sites (epitopes) on the Monkeypox...
From
Enzolytics, Inc.
Via
AccessWire
Topics
Artificial Intelligence
Enzolytics, Inc. Discusses the Significance and Revenue Potential of Its Therapeutic Platforms with The Stock Day Podcast
May 16, 2022
Phoenix, Arizona--(Newsfile Corp. - May 16, 2022) - The Stock Day Podcast welcomed Enzolytics, Inc. (ENZC) ("the Company"), a drug...
Via
Newsfile
CORRECTION: Enzolytics, Inc. Reports Progress and Future Plans
April 25, 2022
This version includes the Safe Harbor statement that was missing from the previous version of this release. COLLEGE STATION, TX / ACCESSWIRE / April 25, 2022 / Enzolytics, Inc. (OTC PINK:ENZC)...
From
Enzolytics, Inc.
Via
AccessWire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.